Milestone Pharmaceuticals (MIST)
Commercializes an etripamil nasal spray for acute adult PSVT episodes.
$1.18
Pre-market+0.00 (+0.34%)
At close$1.18(+3.51%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions86 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 11.73% | 14.61M shares | |
| Insiders8 holders · as of Apr 20, 2026 | 0.88% | 1.10M shares | |
| Strategic holders1 holder · as of May 15, 2026 | 9.93% | 12.36M shares | |
| Otherremainder | ≈ 77.46% | 96.44M shares |
124.50M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Institutions13F, as of Jun 30, 2026
86 holders · 14.61M shares · 7 new positions · 30 increased · 23 reduced · 15 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Pavaki Capital Management LLC | 9.07M | 7.28% | +5.0K | Aug 7, 2026 |
| Two Sigma Investments, LP | 2.04M | 1.64% | −277.2K | Aug 14, 2026 |
| Marshall Wace, LLP | 1.80M | 1.44% | −146.8K | Aug 13, 2026 |
| Ameriprise Financial Inc | 666.7K | 0.54% | 0 | Aug 14, 2026 |
| Susquehanna International Group, LLP | 359.9K | 0.29% | −159.2K | Aug 14, 2026 |
| Guardian Wealth Advisors, LLC / NC | 339.5K | 0.27% | +59.2K | Aug 14, 2026 |
| LPL Financial LLC | 220.9K | 0.18% | +27.5K | Aug 7, 2026 |
| Geode Capital Management, LLC | 40.8K | 0.03% | 0 | Aug 12, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 9.90% | 12.36M | 13G | May 15, 2026 ↗ |
| Propel Bio Management, LLC | 9.90% | 8.86M | 13G | Dec 23, 2025 ↗ |
| Pavaki Capital Management LLC | 7.30% | 9.07M | 13G | Aug 7, 2026 ↗ |
| Adage Capital Management, L.P. | 6.37% | 8.00M | 13G | May 13, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Apr 16, 2026 | Joseph Olivetodirector, officer: President and CEO | Sale | 36,500 | $2.26 | 446,244 |
| Dec 15, 2025 | Joseph Olivetodirector, officer: President and CEO | Sale | 133,054 | $2.32 | 450,667 |
| Jan 26, 2026 | Joseph Olivetodirector, officer: President and CEO | Sale | 34,523 | $1.93 | 482,744 |
| Dec 15, 2025 | Amit Hasijaofficer: CFO & EVP of Corp. Development | Sale | 58,007 | $2.32 | 91,993 |
| Jan 26, 2026 | Amit Hasijaofficer: CFO & EVP of Corp. Development | Sale | 12,245 | $1.93 | 99,848 |
| Dec 15, 2025 | Lorenz Mullerofficer: Chief Commercial Officer | Sale | 53,566 | $2.32 | 196,486 |
| Jan 26, 2026 | Lorenz Mullerofficer: Chief Commercial Officer | Sale | 11,180 | $1.93 | 205,406 |
| Dec 15, 2025 | Jeffrey Edward Nelsonofficer: Chief Operating Officer | Sale | 58,007 | $2.32 | 41,993 |
| Jan 26, 2026 | Jeffrey Edward Nelsonofficer: Chief Operating Officer | Sale | 12,245 | $1.93 | 49,848 |
| Dec 15, 2025 | David Bharuchaofficer: Chief Medical Officer | Sale | 58,007 | $2.32 | 105,326 |
CongressHouse and Senate disclosures
Not reported.